Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Draisma

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
BJU International|February 27, 2004
MISCAN: estimating lead-time and over-detection by simulationG Draisma, H J De Koning
British Journal of Cancer|March 3, 2011
Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deathsR de Gelder, G Draisma, E A M Heijnsdijk, et al.
British Journal of Cancer|August 25, 2011
Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervalsN T van Ravesteyn, E A M Heijnsdijk, G Draisma, et al.
British Journal of Cancer|June 24, 2004
Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortalityM M Vervoort, G Draisma, J Fracheboud, et al.
British Journal of Cancer|July 19, 2012
To be screened or not to be screened? Modeling the consequences of PSA screening for the individualE M Wever, J Hugosson, E A M Heijnsdijk, et al.
British Journal of Cancer|November 12, 2009
Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancerE A M Heijnsdijk, A der Kinderen, E M Wever, et al.
British Journal of Cancer|May 16, 2013
Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factorsE M Wever, E A M Heijnsdijk, G Draisma, et al.
Breast Cancer Research and Treatment|September 28, 2006
Cost-effectiveness of different reading and referral strategies in mammography screening in the NetherlandsJ H Groenewoud, J D M Otten, J Fracheboud, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
BJU International|February 27, 2004
MISCAN: estimating lead-time and over-detection by simulationG Draisma, H J De Koning
British Journal of Cancer|March 3, 2011
Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deathsR de Gelder, G Draisma, E A M Heijnsdijk, et al.
British Journal of Cancer|August 25, 2011
Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervalsN T van Ravesteyn, E A M Heijnsdijk, G Draisma, et al.
British Journal of Cancer|June 24, 2004
Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortalityM M Vervoort, G Draisma, J Fracheboud, et al.
British Journal of Cancer|July 19, 2012
To be screened or not to be screened? Modeling the consequences of PSA screening for the individualE M Wever, J Hugosson, E A M Heijnsdijk, et al.
British Journal of Cancer|November 12, 2009
Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancerE A M Heijnsdijk, A der Kinderen, E M Wever, et al.
British Journal of Cancer|May 16, 2013
Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factorsE M Wever, E A M Heijnsdijk, G Draisma, et al.
Breast Cancer Research and Treatment|September 28, 2006
Cost-effectiveness of different reading and referral strategies in mammography screening in the NetherlandsJ H Groenewoud, J D M Otten, J Fracheboud, et al.
Pageof 1